HomeCompareRECEF vs EPRT

RECEF vs EPRT: Dividend Comparison 2026

RECEF yields 909.09% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RECEF wins by $8252648.15M in total portfolio value
10 years
RECEF
RECEF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full RECEF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RECEF vs EPRT

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRECEFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RECEF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RECEF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, RECEF beats the other by $5,766,875,992,534.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + EPRT for your $10,000?

RECEF: 50%EPRT: 50%
100% EPRT50/50100% RECEF
Portfolio after 10yr
$4126324.14M
Annual income
$3,392,280,008,449.13/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RECEF
No analyst data
Altman Z
-148.3
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys
0
EPRT buys
0
No recent congressional trades found for RECEF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRECEFEPRT
Forward yield909.09%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$8252648.21M$63.4K
Annual income after 10y$6,784,560,004,057.53$12,840.73
Total dividends collected$8138900.96M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RECEF vs EPRT ($10,000, DRIP)

YearRECEF PortfolioRECEF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$101,609$90,909.09$11,205$505.18+$90.4KRECEF
2$972,011$863,288.79$12,672$682.46+$959.3KRECEF
3$8,758,157$7,718,105.75$14,490$930.48+$8.74MRECEF
4$74,364,546$64,993,317.91$16,786$1,282.69+$74.35MRECEF
5$595,318,755$515,748,691.06$19,753$1,791.56+$595.30MRECEF
6$4,495,664,203$3,858,673,134.79$23,677$2,541.64+$4495.64MRECEF
7$32,043,550,537$27,233,189,840.42$29,008$3,672.99+$32043.52MRECEF
8$215,696,715,677$181,410,116,602.38$36,463$5,425.08+$215696.68MRECEF
9$1,372,045,052,584$1,141,249,566,809.58$47,238$8,221.57+$1372045.01MRECEF
10$8,252,648,210,323$6,784,560,004,057.53$63,385$12,840.73+$8252648.15MRECEF

RECEF vs EPRT: Complete Analysis 2026

RECEFStock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RECEF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHDRECEF vs JEPIRECEF vs ORECEF vs KORECEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.